|Chemical and physical data|
|Molar mass||145.2 kg/mol|
Clazakizumab (formerly ALD518 and BMS-945429), an investigational drug, is a aglycosylated, humanized monoclonal antibody against interleukin-6. Clazakizumab was developed by Bristol Myers Squib and Alder Biopharmaceuticals. A preliminary randomized, double-blind, placebo-controlled, phase 2 dose-ranging study of clazakizumab in psoriatic arthritis patients, funded by the manufacturer, suggested that clazakizumab may be an effective treatment option for musculoskeletal aspects of psoriatic arthritis; however, the antibody lacked a dose-response effect.
- Handbook of Therapeutic Antibodies, Volume 2. Wiley Blackwell. 2007. p. 987. Retrieved January 23, 2017.
- Mease PJ, Gottlieb AB; et al. (September 2016). "The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis.". Arthritis Rheumatol. 68 (9): 2163–73. doi:10.1002/art.39700.